Interdisciplinary Healthcare Team Experience of Carboplatin and Oxaliplatin Desensitizations in a Tertiary Referral University Hospital

References

• Otani IM, Wong J, Banerji A. Platinum chemotherapy hypersensitivity: prevalence and management. Immunol Allergy Clin North Am. 2017;37(4):663–677. doi:10.1016/j.iac.2017.06.003
   PubMed Web of Science ®Google Scholar
• Giavina-Bianchi P, Patil SU, Banerji A. Immediate hypersensitivity reaction to chemotherapeutic agents. J Allergy Clin Immunol Pract. 2017;5(3):593–599. doi:10.1016/j.jaip.2017.03.015
   PubMed Web of Science ®Google Scholar
• Vetter MH, Khan A, Backes FJ, et al. Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions. Gynecol Oncol. 2019;152(2):316–321. doi:10.1016/j.ygyno.2018.10.037
   PubMed Web of Science ®Google Scholar
• Weiss ME, Bernstein DI, Blessing-moore J, et al. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010;105(4):259–273.e78. doi:10.1016/j.anai.2010.08.002
   PubMed Web of Science ®Google Scholar
• Caiado J, Picard M. Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators. Curr Allergy Asthma Rep. 2014;14(8). doi:10.1007/s11882-014-0451-7
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Okada R, Ando K. Platinum hypersensitivity and desensitization. Jpn J Clin Oncol. 2015;45(9):795–804. doi:10.1093/jjco/hyv081
   PubMed Web of Science ®Google Scholar
• Castells Guitart MC. Rapid drug desensitization for hypersensitivity reactions to chemotherapy and monoclonal antibodies in the 21st century. J Investig Allergol Clin Immunol. 2014;24(2):72–79.
   PubMed Web of Science ®Google Scholar
• O’Malley DM, Vetter MH, Cohn DE, Khan A, Hays JL. Outpatient desensitization in selected patients with platinum hypersensitivity reactions. Gynecol Oncol. 2017;145(3):603–610. doi:10.1016/j.ygyno.2017.03.015
   PubMed Web of Science ®Google Scholar
• Martí-Garrido J, Vázquez-Revuelta P, Lleonart-Bellfill R, Molina-Mata K, Muñoz-Sánchez C, Madrigal-Burgaleta R. Pilot experience using drug provocation testing for the study of hypersensitivity to chemotherapy and biological agents. J Investig Allergol Clin Immunol. 2021;31(2):166–168. doi:10.18176/JIACI.0552
   PubMed Web of Science ®Google Scholar
• Madrigal-Burgaleta R, Bernal-Rubio L, Berges-Gimeno MP, Carpio-Escalona LV, Gehlhaar P, Alvarez-Cuesta E. A large single-hospital experience using drug provocation testing and rapid drug desensitization in hypersensitivity to antineoplastic and biological agents. J Allergy Clin Immunol Pract. 2019;7(2):618–632. doi:10.1016/J.JAIP.2018.07.031
   PubMed Web of Science ®Google Scholar
• Tunakan Dalgiç C, Mete Gökmen EN, Özişik M, Alkaya Baklan M, Yüceyar N. Successful rapid drug desensitization with a modified protocol to alemtuzumab in a multiple sclerosis patient with severe immediate-type hypersensitivity reaction. Arch Neuropsychiatr. 2022;59(3):237. doi:10.29399/NPA.27371
   Google Scholar
• Choi J, Harnett P, Fulcher DA. Carboplatin desensitization. Ann Allergy Asthma Immunol. 2004;93(2):137–141. doi:10.1016/S1081-1206(10)61465-2
   PubMed Web of Science ®Google Scholar
• Toyohara Y, Sone K, Nishida H, et al. Desensitization strategy for hypersensitivity reactions to carboplatin in five patients with gynecological cancer. J Obstet Gynaecol Res. 2020;46(11):2298–2304. doi:10.1111/jog.14443
   PubMed Web of Science ®Google Scholar
• Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008;122(3):574–580. doi:10.1016/j.jaci.2008.02.044
   PubMed Web of Science ®Google Scholar
• Cernadas JR, Brockow K, Romano A, et al. General considerations on rapid desensitization for drug hypersensitivity - A consensus statement. Allergy. 2010;65(11):1357–1366. doi:10.1111/J.1398-9995.2010.02441.X
   PubMed Web of Science ®Google Scholar
• Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020;13(10):100472. doi:10.1016/j.waojou.2020.100472
   PubMed Web of Science ®Google Scholar
• Picard M, Pur L, Caiado J, et al. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy Clin Immunol. 2016;137(4):1154–1164.e12. doi:10.1016/J.JACI.2015.10.039
   PubMed Web of Science ®Google Scholar
• Hong DI, Madrigal-Burgaleta R, Banerji A, Castells M, Alvarez-Cuesta E. Controversies in allergy: chemotherapy reactions, desensitize, or delabel? J Allergy Clin Immunol Pract. 2020;8(9):2907–2915.e1. doi:10.1016/J.JAIP.2020.08.005
   PubMed Web of Science ®Google Scholar
• Picard M. Management of hypersensitivity reactions to taxanes. Immunol Allergy Clin North Am. 2017;37(4):679–693. doi:10.1016/J.IAC.2017.07.004
   PubMed Web of Science ®Google Scholar
• Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst. 1998;90(4):300–306. doi:10.1093/JNCI/90.4.300
   PubMedGoogle Scholar
• de Leon MCB, Bolla S, Greene B, Hutchinson L, Del Priore G. Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel. Gynecol Oncol Case Rep. 2013;5:70–71. doi:10.1016/J.GYNOR.2013.05.003
   PubMedGoogle Scholar
• Jimenez-Rodriguez TW, Manuel Marco de la Calle F, Lozano-Cubo I, et al. Converter phenotype: a new profile that is not exclusive to taxanes. Front Allergy. 2022;2. doi:10.3389/FALGY.2021.785259
   PubMedGoogle Scholar
• Bonamichi-Santos R, Castells M. Diagnoses and management of drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: reactions to taxanes and monoclonal antibodies. Clin Rev Allergy Immunol. 2018;54(3):375–385. doi:10.1007/S12016-016-8556-5
   PubMed Web of Science ®Google Scholar
• Pradelli J, Verdoire P, Boutros J, et al. Allergy evaluation of hypersensitivity to platinum salts and taxanes: a six-year experience. J Allergy Clin Immunol Pract. 2020;8(5):1658–1664. doi:10.1016/J.JAIP.2019.12.032
   PubMed Web of Science ®Google Scholar
• Li Q, Cohn D, Waller A, et al. Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin. Gynecol Oncol. 2014;135(1):90–94. doi:10.1016/j.ygyno.2014.07.104
   PubMed Web of Science ®Google Scholar
• Dodgshun AJ, Hansford JR, Cole T, Choo S, Sullivan MJ. Carboplatin hypersensitivity reactions in pediatric low grade glioma are protocol specific and desensitization shows poor efficacy. Pediatr Blood Cancer. 2016;63(1):17–20. doi:10.1002/PBC.25686
   PubMed Web of Science ®Google Scholar
• Caiado J, Brás R, Paulino M, Costa L, Castells M. Rapid desensitization to antineoplastic drugs in an outpatient immunoallergology clinic: outcomes and risk factors. Ann Allergy Asthma Immunol. 2020;125(3):325–333.e1. doi:10.1016/J.ANAI.2020.04.017
   PubMed Web of Science ®Google Scholar
• Breslow RG, Caiado J, Castells MC. Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. Ann Allergy Asthma Immunol. 2009;102(2):155–160. doi:10.1016/S1081-1206(10)60247-5
   PubMed Web of Science ®Google Scholar
• Park HJ, Lee JH, Kim SR, et al. A new practical desensitization protocol for oxaliplatin-induced immediate hypersensitivity reactions: a necessary and useful approach. J Investig Allergol Clin Immunol. 2016;26(3):168–176. doi:10.18176/jiaci.0038
   PubMed Web of Science ®Google Scholar
• Madrigal-Burgaleta R, Berges-Gimeno M, Angel-Pereira D, Guillen-Ponce C, Sanz M, Alvarez-Cuesta E. Desensitizing oxaliplatin-induced fever: a case report. J Investig Allergol Clin Immunol. 2013;20(6):435–436.
   Google Scholar
• Stone SF, Cotterell C, Isbister GK, Holdgate A, Brown SGA. Elevated serum cytokines during human anaphylaxis: identification of potential mediators of acute allergic reactions. J Allergy Clin Immunol. 2009;124(4):786–792.e4. doi:10.1016/J.JACI.2009.07.055
   PubMed Web of Science ®Google Scholar
• Jakubovic BD, Sanchez-Sanchez S, Hamadi S, Lynch DM, Castells M. Interleukin-6: a novel biomarker for monoclonal antibody and chemotherapy-associated hypersensitivity confirms a cytokine release syndrome phenotype-endotype association. Allergy. 2021;76(5):1571–1573. doi:10.1111/ALL.14644
   PubMed Web of Science ®Google Scholar
• Liu D, Zhao J. Cytokine release syndrome: grading, modeling, and new therapy. J Hematol Oncol. 2018;11(1). doi:10.1186/S13045-018-0653-X
   Google Scholar
• Silver J, Garcia-Neuer M, Lynch DM, Pasaoglu G, Sloane DE, Castells M. Endophenotyping oxaliplatin hypersensitivity: personalizing desensitization to the atypical platin. J Allergy Clin Immunol Pract. 2020;8(5):1668–1680.e2. doi:10.1016/J.JAIP.2020.02.013
   PubMed Web of Science ®Google Scholar
• Caiado J, Venemalm L, Pereira-Santos MC, Costa L, Barbosa MP, Castells M. Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. J Allergy Clin Immunol Pract. 2013;1(5):494–500. doi:10.1016/J.JAIP.2013.06.002
   PubMed Web of Science ®Google Scholar
• Caiado J, Castells M. Presentation and diagnosis of hypersensitivity to platinum drugs. Curr Allergy Asthma Rep. 2015;15(4). doi:10.1007/S11882-015-0515-3
   PubMed Web of Science ®Google Scholar
• McKenzie MG, Bissell BD, Disselkamp MA, Hildebrandt GC, Cox JN. Sensitizing the interdisciplinary team to desensitizations: an alemtuzumab case report. J Oncol Pharm Pract. 2020;26(3):742–746. doi:10.1177/1078155219865313
   PubMed Web of Science ®Google Scholar
• Amorós-Reboredo P, Sánchez-López J, Bastida-Fernández C, et al. Desensitization to rituximab in a multidisciplinary setting. Int J Clin Pharm. 2015;37(5):744–748. doi:10.1007/s11096-015-0136-x
   PubMed Web of Science ®Google Scholar
• Narui C, Tanabe H, Shapiro JS, et al. Readministration of platinum agents in recurrent ovarian cancer patients who developed hypersensitivity reactions to carboplatin. In vivo. 2019;33(6):2045–2050. doi:10.21873/invivo.11702
   PubMed Web of Science ®Google Scholar
• Sloane D, Govindarajulu U, Harrow-Mortelliti J, et al. Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies. J Allergy Clin Immunol Pract. 2016;4(3):497–504. doi:10.1016/J.JAIP.2015.12.019
   PubMed Web of Science ®Google Scholar